Սոլպադեին

main_info

  • trade_name:
  • Սոլպադեին Ակտիվ
  • dosage:
  • (500մգ+65մգ)(12/2x6/), ստրիպում
  • pharmaceutical_form:
  • դեղահատեր լուծվող
  • prescription_type:
  • Առանց դեղատոմսի
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic

documents

localization

  • country:
  • Սոլպադեին Ակտիվ
    አርሜኒያ
  • language:
  • አማርኛ

other_info

status

  • source:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • last_update:
  • 31-05-2018

6-3-2019

Caffeine

Caffeine

Caffeine is a substance naturally present in over 60 different plants, including coffee, kola nut, guarana and yerba maté. It is most commonly consumed in coffee and tea, but it is also found in energy drinks. ANSES recommends that consumers use moderation with regard to caffeine - especially children, pregnant women and individuals who are either sensitive to its effects or who suffer from certain pathologies.

France - Agence Nationale du Médicament Vétérinaire

12-12-2018

Spilling the Beans: How Much Caffeine is Too Much?

Spilling the Beans: How Much Caffeine is Too Much?

In what foods is caffeine found? Can caffeine pose a danger to your health? This Consumer Update answers these and other key questions about caffeine.

FDA - U.S. Food and Drug Administration

5-6-2018

FDA warns companies to stop selling dangerous and illegal pure and highly concentrated caffeine products

FDA warns companies to stop selling dangerous and illegal pure and highly concentrated caffeine products

FDA issued warning letters to the parties responsible for liquidcaffeine.com and Dual Health Body and Mind for illegally selling certain highly concentrated caffeine products.

FDA - U.S. Food and Drug Administration

27-2-2014

Paracetamol use during pregnancy

Paracetamol use during pregnancy

A new Danish study suggests a possible connection between mothers' use of paracetamol painkillers during pregnancy and the risk of developing disorders like ADHD (attention deficit hyperactivity disorder) in children.

Danish Medicines Agency

3-8-2012

Danish Pharmacovigilance Update, 21 June 2012

Danish Pharmacovigilance Update, 21 June 2012

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Decrease in the number of intoxications and suicide attempts using drugs containing acetylsalicylic acid or paracetamol.

Danish Medicines Agency

23-4-2019


Paracetamol (IV formulation): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002311/201805

Paracetamol (IV formulation): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002311/201805

Paracetamol (IV formulation): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002311/201805

Europe - EMA - European Medicines Agency

23-4-2019


Paracetamol (IV formulation): List of nationally authorised medicinal products - PSUSA/00002311/201805

Paracetamol (IV formulation): List of nationally authorised medicinal products - PSUSA/00002311/201805

Paracetamol (IV formulation): List of nationally authorised medicinal products - PSUSA/00002311/201805

Europe - EMA - European Medicines Agency

10-4-2019


Paracetamol / pseudoephedrine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002307/201806

Paracetamol / pseudoephedrine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002307/201806

Paracetamol / pseudoephedrine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002307/201806

Europe - EMA - European Medicines Agency

5-4-2019


Paracetamol/pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00002307/201806

Paracetamol/pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00002307/201806

Paracetamol/pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00002307/201806

Europe - EMA - European Medicines Agency

26-3-2019


Paracetamol / tramadol: List of nationally authorised medicinal products - PSUSA/00002310/201808

Paracetamol / tramadol: List of nationally authorised medicinal products - PSUSA/00002310/201808

Paracetamol / tramadol: List of nationally authorised medicinal products - PSUSA/00002310/201808

Europe - EMA - European Medicines Agency

27-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Ibuprofen,Paracetamol, decision type: , therapeutic area: , PIP number: P/0135/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ibuprofen,Paracetamol, decision type: , therapeutic area: , PIP number: P/0135/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ibuprofen,Paracetamol, decision type: , therapeutic area: , PIP number: P/0135/2018

Europe - EMA - European Medicines Agency

30-8-2018

Consultation: Referral of proposed amendment to the current Poisons Standard to the meeting of the ACMS, March 2019

Consultation: Referral of proposed amendment to the current Poisons Standard to the meeting of the ACMS, March 2019

Advisory Committee on Medicines Scheduling to consider upscheduling of modified release paracetamol to 'Pharmacist Only'. Closing date 31 October 2018

Therapeutic Goods Administration - Australia

30-8-2018

Modified release paracetamol

Modified release paracetamol

Advisory Committee on Medicines Scheduling to consider upscheduling of modified release paracetamol to 'Pharmacist Only'

Therapeutic Goods Administration - Australia